title: Intracoronary infusion of CD133+ and CD133-CD34+ selected autologous bone marrow progenitor cells in patients with chronic ischemic cardiomyopathy: cell isolation, adherence to the infarcted area, and body distribution.
abstract: Central issues in intracoronary infusion (ICI) of bone marrow (BM)-cells to damaged myocardium for improving cardiac function are the cell number that is feasible and safe to be administrated as well as the retention of cells in the target area. Our study addressed these issues in eight patients with chronic ischemic cardiomyopathy undergoing ICI of selected BM-progenitors. We could immunomagnetically isolate 0.8 +/- 0.32 x 10(7) CD133(+) cells and 0.75 +/- 0.24 x 10(7) CD133(-)CD34(+) cells from 310 +/- 40 ml BM. After labeling these cells with (99m)Tc-hexamethylpropylenamineoxime, they were infused into the infarct-related artery without any complication. Scintigraphic images 1 (eight patients) and 24 hours (four patients) after ICI revealed an uptake of 9.2% +/- 3.6 and 6.8% +/- 2.4 of the total infused radioactivity in the infarcted area of the heart, respectively; the remaining activity was distributed mainly to liver and spleen. We conclude that through ICI of CD133(+) and CD133(-)CD34(+) BM-progenitors a significant number of them are preferentially attracted to and retained in the chronic ischemic myocardium.
authors.affiliation: Stem Cell Transplant Unit, Aghia Sophia Children's Hospital, Thivon and Levadias, 11527 Athens, Greece. bmtlab@paidon-agiasofia.gr
authors.forename: Evgenios
authors.initials: E
authors.lastname: Goussetis
authors.forename: Athanassios
authors.initials: A
authors.lastname: Manginas
authors.forename: Maria
authors.initials: M
authors.lastname: Koutelou
authors.forename: Ioulia
authors.initials: I
authors.lastname: Peristeri
authors.forename: Maria
authors.initials: M
authors.lastname: Theodosaki
authors.forename: Nikolaos
authors.initials: N
authors.lastname: Kollaros
authors.forename: Evangelos
authors.initials: E
authors.lastname: Leontiadis
authors.forename: Athanasios
authors.initials: A
authors.lastname: Theodorakos
authors.forename: George
authors.initials: G
authors.lastname: Paterakis
authors.forename: George
authors.initials: G
authors.lastname: Karatasakis
authors.forename: Dennis V
authors.initials: DV
authors.lastname: Cokkinos
authors.forename: Stelios
authors.initials: S
authors.lastname: Graphakos
mesh_terms: D000071916:AC133 Antigen; D000328:Adult; D015703:Antigens, CD / Q000276:immunology*; D018952:Antigens, CD34 / Q000276:immunology*; D001854:Bone Marrow Cells / Q000166:cytology* / Q000276:immunology; D016026:Bone Marrow Transplantation / Q000379:methods; D002908:Chronic Disease; D005434:Flow Cytometry; D005500:Follow-Up Studies; D006023:Glycoproteins / Q000276:immunology*; D006801:Humans; D008297:Male; D008875:Middle Aged; D017202:Myocardial Ischemia / Q000473:pathology / Q000601:surgery*; D009206:Myocardium / Q000276:immunology / Q000473:pathology; D010455:Peptides / Q000276:immunology*; D013234:Stem Cells / Q000166:cytology* / Q000276:immunology; D014182:Transplantation, Autologous
chemical_list: D000071916:AC133 Antigen; D015703:Antigens, CD; D018952:Antigens, CD34; D006023:Glycoproteins; C000606023:PROM1 protein, human; D010455:Peptides